'); //--> Back to Boston.com homepage Arts | Entertainment Boston Globe Online Cars.com BostonWorks Real Estate Boston.com Sports digitalMass Travel
Home
Help

Top Ten
1. Charles River Labs
2. TJX
3. Perini
4. Investors Fin. Svcs.
5. Gillette
6. Staples
7. OneSource
8. Reebok
9. Bright Horizons
10. State Street
2002 Globe 100

Year's Best
Company of year
Highest market value
Highest sales
Comeback of the year
Biggest stock gain
Fastest growth

Features
Overall performance
Bulls and Bears
  Bulls
  1. Clean Harbors
  2. Hologic
  3. NMT Medical
  4. DeWolfe
  5. Indevus Pharm.
  Bears
  1. Sonus Networks
  2. Art Tech. Group
  3. Praecis Pharm.
  4. American Tower
  5. Dusa Pharmaceutical
Banking
Market value
Sales
Biotech
Medical devices
Growth
  1. Cytyc
  2. Polymedica Corp.
  3. Perini
  4. Tweeter
  5. Boston Private Fin.
Telecom
Employment
Technology
IPOs
Company profiles
Globe 100 notes

Get the chart
The 2002 Globe 100
All the charts


Sections Boston Globe Online: Page One Nation | World Metro | Region Business Sports Living | Arts Editorials


Search the Globe:

Today
Yesterday

The Boston Globe OnlineBoston.com The Best in Massachusetts Business
BEARS
5.  D U S A   P H A R M A C E U T I C A L S    I N C .

Biotech firm has potential, but sales sluggish

    Globe 100
Bulls:
  1. Clean Harbors
  2. Hologic
  3. NMT Medical
  4. DeWolfe
  5. Indevus Pharmaceuticals

Bears:
  1. Sonus Networks
  2. Art Technology Group
  3. Praecis Pharmaceutical
  4. American Tower
  5. Dusa Pharmaceutical

Get the chart
   The Bulls
   The Bears
   All the charts

Dusa, of Wilmington, is in an enviable position for a young biotech firm with negligible sales.

In contrast with many of its brethren, Dusa has an actual, approved product: a solution that makes cells sensitive to certain types of light. It is applied to precancerous lesions of the scalp and face and zapped with a proprietary light source. Dusa says its system offers a quicker, less painful method of removal, compared to freezing the skin or applying certain chemicals.

The company ended 2001 with more than $75 million in the bank. And it has a development and marketing agreement with Berlex Laboratories Inc., the US affiliate of German drug giant Schering AG.

So why did Dusa's stock drop $9.30, nearly 70 percent, to close the year ended March 31 at $4.01?

According to regulatory filings, Dusa hasn't sold many of its BLU-U light units or much of its Levulan Kerastick solution.

In January 2001, Dusa had to pay $100,000 to its light unit supplier, National Biological Corp., because it had not ordered the minimum number of units.

In February 2001, Dusa amended a separate agreement with North Safety Products Inc., which makes the solution applicator, also because of "underutilization." Dusa paid North Safety $1.2 million last year, with another $200,000 due by year's end. It may have to pay additional "underutilization" charges of up to $500,000, depending on production levels through June 2003.

It all adds up to a lot of out-of-pocket expenses for a company that had revenues of only $5.4 million in 2001. Dusa said it hopes new insurance reimbursement codes and continued education and marketing programs will build demand for the lesion therapy while it continues to develop its system for different skin problems and other medical conditions. However, the company said in a news release, "For 2002, Dusa is not anticipating a significant change in revenues."

JEFFREY KRASNER


© Copyright 2002 Boston Globe Electronic Publishing Inc.
| Advertise | Contact us | Privacy policy |





Sponsors of the Globe 100 breakfast